BACKGROUND: The purpose of this work was to examine the ability of an oncolytic vaccinia virus expressing the human sodium iodine transporter (hNIS) to provide real time monitoring of viral therapy and effective treatment of malignant pleural mesothelioma (MPM). METHODS: Infectivity and cytotoxic effects of GLV-1h153 on mesothelioma cell lines of all histologic subtypes were assayed in vitro. Viral replication was examined by standard viral plaque assay. Orthotopic MPM xenografts were generated in athymic nude mice, treated with intrapleural GLV-1h153, and assessed for effect on tumor burden and survival. Orthotopic tumors were also imaged on single photon emission computed tomography (SPECT)/computed tomography (CT) after (131)I administration. RESULTS: GLV-1h153-infected and killed all cell lines in a time- and concentration-dependent manner. Viral replication demonstrated a >2.5-log increase in titer over 4 days. Intrapleural treatment of orthotopic MPM xenografts resulted in a significant decrease in tumor burden 1 week after treatment and an improvement in survival. Infection of orthotopic xenografts was both therapeutic and facilitated monitoring by (131)I-SPECT/CT via expression of hNIS in infected tissue. CONCLUSION: Our results suggest that GLV-1h153 may be a promising therapeutic agent for MPM and warrants further investigation.
BACKGROUND: The purpose of this work was to examine the ability of an oncolytic vaccinia virus expressing the humansodium iodine transporter (hNIS) to provide real time monitoring of viral therapy and effective treatment of malignant pleural mesothelioma (MPM). METHODS: Infectivity and cytotoxic effects of GLV-1h153 on mesothelioma cell lines of all histologic subtypes were assayed in vitro. Viral replication was examined by standard viral plaque assay. Orthotopic MPM xenografts were generated in athymic nude mice, treated with intrapleural GLV-1h153, and assessed for effect on tumor burden and survival. Orthotopic tumors were also imaged on single photon emission computed tomography (SPECT)/computed tomography (CT) after (131)I administration. RESULTS:GLV-1h153-infected and killed all cell lines in a time- and concentration-dependent manner. Viral replication demonstrated a >2.5-log increase in titer over 4 days. Intrapleural treatment of orthotopic MPM xenografts resulted in a significant decrease in tumor burden 1 week after treatment and an improvement in survival. Infection of orthotopic xenografts was both therapeutic and facilitated monitoring by (131)I-SPECT/CT via expression of hNIS in infected tissue. CONCLUSION: Our results suggest that GLV-1h153 may be a promising therapeutic agent for MPM and warrants further investigation.
Authors: Sepideh Gholami; Dana Haddad; Chun-Hao Chen; Nanhai G Chen; Qian Zhang; Pat B Zanzonico; Aladar A Szalay; Yuman Fong Journal: Surgery Date: 2011-12 Impact factor: 3.982
Authors: Qian Zhang; Yong A Yu; Ena Wang; Nanhai Chen; Robert L Danner; Peter J Munson; Francesco M Marincola; Aladar A Szalay Journal: Cancer Res Date: 2007-10-15 Impact factor: 12.701
Authors: Prasad S Adusumilli; Brendon M Stiles; Mei-Ki Chan; Michael Mullerad; David P Eisenberg; Leah Ben-Porat; Rumana Huq; Valerie W Rusch; Yuman Fong Journal: J Gene Med Date: 2006-05 Impact factor: 4.565
Authors: Dana Haddad; Pat B Zanzonico; Sean Carlin; Chun-Hao Chen; Nanhai G Chen; Qian Zhang; Yong A Yu; Valerie Longo; Kelly Mojica; Richard J Aguilar; Aladar A Szalay; Yuman Fong Journal: J Nucl Med Date: 2012-11-08 Impact factor: 10.057
Authors: Silvia Ravera; Andrea Reyna-Neyra; Giuseppe Ferrandino; L Mario Amzel; Nancy Carrasco Journal: Annu Rev Physiol Date: 2017-02-10 Impact factor: 19.318